INNOVANCE Anti-Xa assaySimplify your anticoagulant testing

The INNOVANCE® Anti-Xa assay1 is an automated chromogenic assay for the quantitative determination of the activity of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) as well as rivaroxaban, apixaban and edoxaban concentrations in citrated human plasma. The INNOVANCE Anti-Xa assay1 combines a truly ready-to-use liquid reagent for heparin and DOAC testing, allowing 24/7 access to rapid, specific testing for anticoagulants. Unlike most commercially-available solutions, this assay requires no manual preparation or waiting time. INNOVANCE Anti-Xa assay has now been extended to test for edoxaban.

Siemens Healthineers Hemostasis INNOVANCE Anti-Xa assay

Benefits

Economical testing outcomes
  • Liquid reagents require no manual preparation or reconstitution, allowing staff to concentrate on high-value tasks.
  • Combined testing solution reduces handling, material, and ordering complexity for the lab.
  • Single calibration curve for both types of heparin (UFH and LMWH) streamlines result interpretation and eliminates the risk of evaluation on the wrong curve.
No wait icon
  • 24/7 access to rapid, specific testing for anticoagulants supports timely patient treatment.
  • Robust assay design reduces susceptibility to interferences.
Patient outcomes
  • Drug-specific standards sets for the DOACs rivaroxaban, apixaban and edoxaban allow for accurate measurement of drug concentrations in ng/mL.
  • Broad and consistent assay range of 0.10 to 1.50 IU/mL for UF and LMW heparin, extendable up to 2.25 IU/mL by sample dilution.
  • High lot-to-lot consistency that helps ensure consistent patient results over time.
Economical testing outcomes
  • Liquid reagents require no manual preparation or reconstitution, allowing staff to concentrate on high-value tasks.
  • Combined testing solution reduces handling, material, and ordering complexity for the lab.
  • Single calibration curve for both types of heparin (UFH and LMWH) streamlines result interpretation and eliminates the risk of evaluation on the wrong curve.

Technical Details

The INNOVANCE Anti-Xa assayoffers robust performance across all parameters. With its compact and ready-to-use configuration, the INNOVANCE Anti-Xa assay supports improved laboratory outcomes. It builds on the proven performance of the INNOVANCE Heparin assay and leverages the same proven components, but now also includes DOAC testing capabilities.

Technical Specifications

0.10–1.50 IU/mL

Consistent measuring range for UFH and LMWH, extendable up to 2.25 IU/mL by sample dilution

20–350 ng/mL

Measuring range for rivaroxaban, apixaban and edoxaban, extendable up to 700 ng/mL by sample dilution

Technical Specifications

1.0%

Within-device/lab CV of INNOVANCE Heparin LMW Control 1

2.48%

Within-device/lab CV of INNOVANCE Apixaban Control 11

2.13%

Within-device/lab CV of INNOVANCE Rivaroxaban Control 11

2.0 ng/mL

Within device/Lab SD for INNOVANCE Edoxaban Control 11


Within-device/lab CV (%) indicated for CS-2500 System. Assay performance can vary from country to country as well as corresponding to the system application of the respective assay. The values listed above are provided as examples only. 


Technical Specifications

8 weeks

Stability once opened at 2–8°C

Evidence

By combining heparin and DOAC testing into one simple and easy-to-use assay, the INNOVANCE Anti-Xa assaystreamlines handling, reduces order complexity, and offers labs an economical testing outcome.

    Siemens-Healthineers-Hemostasis-reagent-portfolio-cover

    For details on available assay applications or ordering information, download a copy of the hemostasis reagent portfolio catalogue.

    Clinical Use

    Why your lab should perform anti-Xa testing for anticoagulants

    To monitor and manage bleeding risks, labs are asked to safeguard anticoagulant therapies such as heparin or direct oral anticoagulants (DOACs) by testing patients for a growing number of agents.

    Why accurate DOAC assessment is imperative

    Direct oral anticoagulants such as rivaroxaban, apixaban and edoxaban are direct anti-Xa inhibitor drugs that have evolved over time because of their convenient dosing and short half-life. Though the medication usually does not require monitoring, DOAC testing is needed to properly manage individuals with bleeding conditions, in emergency situations that require unplanned surgery, and relevant comorbidities (e.g., renal insufficiency).

    Why anti-Xa is the better choice for heparin testing

    Heparin is a traditional anticoagulant drug and exists in two forms—UFH and LMWH—both of which considerably accelerate the inactivation of coagulation factor Xa by antithrombin. Clinical data shows that monitoring heparin with an anti-Xa assay has several advantages over APTT testing:2-6

    • A smoother dose-response curve 
    •  More-stable heparin levels during therapy 
    •  Fewer blood samples required 
    •  Fewer dosage adjustments

    Downloads

    Services

    Related Products, Services & Resources

    Lab tech sorting tubes

    Solutions to meet the needs of every hemostasis lab

    Let Siemens Healthineers power up your lab with a comprehensive portfolio of hemostasis products.

    Siemens-Healthineers-Hemostasis-Assays

    Have you powered up your lab with INNOVANCE reagents?

    The INNOVANCE® line is an example of our longstanding commitment to help answer the concrete challenges of laboratories like yours.

    Hemostasis Science Weeks

    PEPconnect

    Find out more about the education and performance experience for healthcare professionals.


    1
    2
    3
    4
    5
    6